HIV type 1 tropism and inhibitors of viral entry: Clinical implications

AIDS Reviews

Volumn 8, Issue 2, 2006, Pages 60-77

  Weber, Jan ^a   Piontkivska, Helen ^b   Quiñones Mateu, Miguel E ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CCR5; Coreceptor; CXCR4; Entry inhibitors; HIV

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 4,4' [CARBONYLBIS[IMINO 1H PYRROLE 4,2 DIYLCARBONYLIMINO(1 METHYL 1H PYRROLE 4,2 DIYL)CARBONYLIMINO]]BIS(1,7 NAPHTHALENESULFONIC ACID); ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMD 070; ANTIRETROVIRUS AGENT; APLAVIROC; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; COSALANE; CYANOVIRIN N; DEXTRAN SULFATE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MARAVIROC; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PRO 140; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; VIRUS RECEPTOR; ZINTEVIR;

ACCURACY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMPUTER MODEL; DISEASE COURSE; DRUG ABSORPTION; DRUG SYNTHESIS; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LIVER TOXICITY; MEDICAL RESEARCH; MEDLINE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN INTERACTION; PUBLICATION; REVIEW; SINGLE DRUG DOSE; VIRUS REPLICATION;

ANIMALS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 33745893769     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (248)

1. Dalgleish A, Beverley P, Clapham P, Crawford D, Greaves M, Weiss R. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 1984;312:763-7.
2. Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (London) 1984;312:767-8.
3. Levy J. HIV and the pathogenesis of AIDS. Washington, D.C.: ASM Press, 1994.
4. Levy J. Pathogenesis of HIV infection. Microbiol Rev 1993;57:183-289.
5. Cocchi F, DeVico A, Garzino-Demo A, Arya S, Gallo R, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells (see comments). Science 1995;270:1811-15.
6. Dragic T, Litwin V, Allaway G, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5. Nature (London) 1996;381:667-73.
7. Feng Y, Broder C, Kennedy P, Berger E. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane. G protein-coupled receptor. Science 1996;272:872-7.
8. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature (London) 1996;381:661-6.
9. Tersmette M, de Goede R, Al B, et al. Differential syncytium-inducing capacity of HIV isolates: frequent detection of syncytium-inducing isolates in patients with AIDS and AIDS-related complex. J Virol 1988;62:2026-32.
10. Fenyo E, Morfeldt-Manson L, Chiodi F, et al. Distinct replicative and cytopathic characteristics of HIV isolates. J Virol 1988;62:4414-9.
11. Fenyo E, Albert J, Asjo B. Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 1989;3 Suppl 1:S5-12.
12. Fenyo E, Schuitemaker H, Asjö B, McKeating J, Sattentau Q. EC Concerted Action. HIV Variability. The History of HIV-1 Biological Phenotypes. Past, Present and Future. Review in 1997 Human Retroviruses and AIDS Compendium 2000.
13. Schuitemaker H, Koot M, Kootstra N, et al. Biological phenotype of HIV-1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-60.
14. Berger E, Doms R, Fenyo E, et al. A new classification for HIV-1. Nature (London) 1998;391:240.
15. Berger E, Murphy P, Farber J. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
16. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary HIV-1 isolates varies according to biological phenotype. J Virol 1997;71:7478-87.
17. O'Brien S, Moore J. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000;177:99-111.
18. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62.
19. Blauvelt A, Glushakova S, Margolis LB. HIV-infected human Langerhans cells transmit infection to human lymphoid tissue ex vivo. AIDS 2000;14:647-51.
20. Soto-Ramirez L, Renjifo B, McLane M, et al. HIV-1 Langerhans cell tropism associated with heterosexual transmission of HIV. Science 1996;271:1291-3.
21. Van Opijnen T, Berkhout B. The host environment drives HIV-1 fitness. Rev Med Virol 2005;15:219-33.
22. Asjo B, Morfeldt-Manson L, Albert J, et al. Replicative capacity of HIV from patients with varying severity of HIV infection. Lancet 1986;2:660-662.
23. Connor R, Ho D. HIV-1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994;68:4400-08.
24. Richman D, Bozzette S. The impact of the syncytium-inducing phenotype of HIV on disease progression. J Infect Dis 1994; 169:968-74.
25. Van Rij R, Blaak H, Visser J, et al. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest 2000;106:1039-52.
26. Bleul C, Wu L, Hoxie J, Springer T, Mackay C. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-30.
27. Quinones-Mateu M, Arts E. Virus fitness: concept, quantification, and application to HIV population dynamics. Curr Top Microbiol Immunol 2006;299:83-140.
28. Quinones-Mateu M, Arts E. HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, et al. eds. HIV Sequence Compendium 2001. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2001:134-70.
29. Jensen M, 't Wout A. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003;5:104-12.
30. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006;in press.
31. Cheng-Mayer C, Shioda T, Levy J. Host range, replicative, and cytopathic properties of HIV-1 are determined by very few amino acid changes in tat and gp120. J Virol 1991;65:6931-41.
32. Cheng-Mayer C, Liu R, Landau N, Stamatatos L. Macrophage tropism of HIV-1 and utilization of the CC-CKR5 coreceptor. J Virol 1997;71:1657-61.
33. Cheng-Mayer C, Quiroga M, Tung J, Dina D, Levy J. Viral determinants of HIV-1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol 1990;64:4390-8.
34. Hwang S, Boyle T, Lyerly H, Cullen B. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-4.
35. De Jong J, Goudsmit J, Keulen W, et al. HIV-1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992;66:757-65.
36. Fouchier R, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the HIV-1 gp120 molecule. J Virol 1992;66:3183-7.
37. Zhong P, Peeters M, Janssens W, et al. Correlation between genetic and biological properties of biologically cloned HIV-1 viruses representing subtypes A, B, and D. AIDS Res Hum Retroviruses 1995;11:239-48.
38. Holm-Hansen C, Baan E, Asjo B, Pascu F, Goudsmit J, de Jong J. Determinants for the syncytium-inducing phenotype of HIV-1 subtype F isolates are located in the V3 region. AIDS Res Hum Retroviruses 2000;16:867-70.
39. Andeweg A, Leeflang P, Osterhaus A, Bosch M. Both the V2 and V3 regions of the HIV-1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol 1993;67:3232-9.
40. Boyd M, Simpson G, Cann A, Johnson M, Weiss R. A single amino acid substitution in the V1 loop of HIV-1 gp120 alters cellular tropism. J Virol 1993;67:3649-52.
41. Groenink M, Fouchier R, Broersen S, et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993; 260:1513-6.
42. Groenink M, Andeweg A, Fouchier R, et al. Phenotype-associated env gene variation among eight related HIV-1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J Virol 1992;66:6175-80.
43. Jansson M, Backstrom E, Scarlatti G, et al. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2001;17:1405-14.
44. Hoffman N, Seillier-Moiseiwitsch F, Ann J, Walker J, Swanstrom R. Variability in the HIV-1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002;76:3852-64.
45. Tersmette M, Gruters R, de Wolf F, et al. Evidence for a role of virulent HIV variants in the pathogenesis of AIDS: studies on sequential HIV isolates. J Virol 1989;63:2118-25.
46. Koot M, Vos A, Keet R, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 co-cultivation assay. AIDS 1992;6:49-54.
47. Bozzette S, McCutchan J, Spector S, Wright B, Richman D. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing HIV. J Infect Dis 1993;168:1374-9.
48. Coakley E, Petropoulos C, Whitcomb J. Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis 2005;18:9-15.
49. Schuitemaker H, Kootstra N. Determination of coreceptor usage of HIV-1. Methods Mol Biol 2005;304:327-32.
50. Vodicka M, Goh W, Wu L, et al. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997;233:193-8.
51. Soda Y, Shimizu N, Jinno A, et al. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 1999;258:313-21.
52. Morner A, Bjorndal A, Albert J, et al. Primary HIV-2 isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999;73:2343-9.
53. Trkola A, Ketas T, KewalRamani V, et al. Neutralization sensitivity of HIV-1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998;72:1876-85.
54. Jekle A, Schramm B, Jayakumar P, et al. Coreceptor phenotype of natural HIV with nef deleted evolves in vivo, leading to increased virulence. J Virol 2002;76:6966-73.
55. Zhang Y, Lou B, Lal R, Gettie A, Marx P, Moore J. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and HIV type 2 in primary cells. J Virol 2000;74:6893-910.
56. Meyerhans A, Cheynler R, Albert J, et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989;58:901-10.
57. Trouplin V, Salvatori F, Cappello F, et al. Determination of coreceptor usage of HIV-1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001;75:251-9.
58. Carroll R, Riley J, Levine B, et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 co-stimulation of CD4+ T-cells. Science 1997;276:273-6.
59. Reeves J, Gallo S, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002;99:16249-54.
60. Labrosse B, Labernardiere J, Dam E, et al. Baseline susceptibility of primary HIV-1 to entry inhibitors. J Virol 2003;77:1610-3.
61. De Jong J, Simon F, van der Groen G, et al. V3 loop sequence analysis of seven HIV-1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells. AIDS Res Hum Retroviruses 1996;16:1503-7.
62. Milich L, Margolin B, Swanstrom R. V3 Loop of the HIV-1 Env protein: interpreting sequence variability. J Virol 1993;67:5623-34.
63. Fouchier R, Brouwer M, Broersen S, Schuitemaker H. Simple determination of HIV-1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 1995;33:906-11.
64. Milich L, Margolin B, Swanstrom R. Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology 1997;239:108-18.
65. Wyatt R, Thali M, Tilley S, et al. Relationship of the HIV-1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J Virol 1992;66:6997-7004.
66. Moore J, Thali M, Jameson B, et al. Immunochemical analysis of the gp120 surface glycoprotein of HIV-1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J Virol 1993;67:4785-96.
67. Van Rij R, Worobey M, Visser J, Schuitemaker H. Evolution of R5 and X4 HIV-1 gag sequences in vivo: evidence for recombination. Virology 2003;314:451-9.
68. Korber B, Farber R, Wolpert D, Lapedes A. Co-variation of mutations in the V3 loop of HIV-1 envelope protein: an information theoretic analysis. Proc Natl Acad Sci USA 1993;90:7176-80.
69. Bickel P, Cosman P, Olshen R, Spector P, Rodrigo A, Mullins J. Co-variability of V3 loop amino acids. AIDS Res Hum Retroviruses 1996;12:1401-11
70. Jensen M, Li F, 't Wout A, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV-1 env V3 loop sequences. J Virol 2003;77:13376-88.
71. Reche P, Glutting J, Reinherz E. Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 2002;63:701-9.
72. Beerenwinkel N, Sing T, Lengauer T, et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 2005;21:3943-50.
73. Sing T, Beerenwinkel N, Lengauer T. Learning mixtures of localized rules by maximizing the area under the ROC curve. 16th European Conference on Artificial Intelligence (ECAI), Workshop on ROC Analysis in AI, 2004 (accepted). 2004.
74. Pillai S, Good B, Richman D, Corbeil J. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003;19:145-9.
75. Moore J, Doms R. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003;100:10598-602.
76. Ashkenazi A, Smith D, Marsters S, et al. Resistance of primary isolates of HIV-1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc Natl Acad Sci USA 1991;88:7056-60.
77. Allaway G, Davis-Bruno K, Beaudry G, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995;11:533-9.
78. Trkola A, Pomales A, Yuan H, et al. Cross-clade neutralization of primary isolates of HIV-1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-17.
79. Gauduin M, Allaway G, Maddon P, Barbas C III, Burton D, Koup R. Effective ex vivo neutralization of HIV-1 in plasma by recombinant immunoglobulin molecules. J Virol 1996;70:2586-92.
80. Zhu P, Olson W, Roux K. Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking HIV-1 envelope spikes. J Virol 2001;75:6682-6.
81. Jacobson J, Lowy I, Fletcher C, et al. Single-dose safety, pharmacology, and antiviral activity of the HIV-1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000;182:326-9.
82. Martin L, Stricher F, Misse D, et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 2003;21:71-6.
83. Kuritzkes D, Jacobson J, Powderly W, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004;189:286-91.
84. Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib D, Mostowski H, Norcross M. Mediation of HIV-1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 1995;69:2233-9.
85. Moulard M, Lortat-Jacob H, Mondor I, et al. Selective interactions of polyanions with basic surfaces on HIV-1 gp120. J Virol 2000; 74:1948-60.
86. Long D, Berson J, Cook D, Doms R. Characterization of HIV-1 gp120 binding to liposomes containing galactosylceramide. J Virol 1994;68:5890-8.
87. Nguyen D, Hildreth J. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur J Immunol 2003;33:483-93.
88. Geijtenbeek T, Torensma R, van Vliet S, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000;100:575-85.
89. Llao Z, Roos J, Hildreth J. Increased infectivity of HIV-1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res Hum Retroviruses 2000;16:355-66.
90. Hioe C, Chien P, Lu C, et al. LFA-1 expression on target cells promotes HIV-1 infection and transmission. J Virol 2001;75:1077-82.
91. Delezay O, Hammache D, Fantini J, Yahi N. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. Biochemistry 1996;35:15663-71.
92. Barbouche R, Papandreou M, Miquelis R, Guieu R, Fenouillet E. Relationships between the anti-HIV V(3)-derived peptide SPC(3) and lymphocyte membrane properties involved in virus entry: SPC(3) interferes with CXCR(4). FEMS Microbiol Lett 2000;183:235-40.
93. De Mareuil J, Mabrouk K, Doria E, et al. Liposomal encapsulation enhances antiviral efficacy of SPC3 against HIV-1 infection in human lymphocytes. Antiviral Res 2002;54:175-88
94. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of HIV in vitro. Proc Natl Acad Sci USA 1988;85:6132-6.
95. Hiebert L, Wice S, Jaques L, Williams K, Conly J. Orally administered dextran sulfate is absorbed in HIV-positive individuals. J Lab Clin Med 1999;133:161-70.
96. Pereira C, Paridaen J. Anti-HIV drug development-an overview. Curr Pharm Des 2004;10:4005-37.
97. De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002;22:531-65.
98. De Clercq E. HIV chemotherapy and prophylaxis: new drugs, leads and approaches. Int J Biochem Cell Biol 2004;36:1800-22.
99. Santhosh K, Paul G, De Clercq E, et al. Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores. J Med Chem 2001;44:703-14.
100. Halliday S, Lackman-Smith C, Bader J, et al. Inhibition of HIV replication by the sulfonated stilbene dye resobene. Antiviral Res 1996;33:41-53.
101. Dezube B, Dahl T, Wong T, et al. A fusion inhibitor (FP-21399) for the treatment of HIV infection: a phase I study. J Infect Dis 2000;182:607-10.
102. Ojwang J, Buckheit R, Pommier Y, et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of HIV-1. Antimicrob Agents Chemother 1995;39:2426-35.
103. Este J, Cabrera C, Schols D, et al. HIV glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol 1998;53:340-5.
104. Wang T, Zhang Z, Wallace O, et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003;46:4236-9.
105. Lin P, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003;100:11013-8.
106. Guo Q, Ho H, Dicker I, et al. Biochemical and genetic characterizations of a novel HIV-1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003;77:10528-36.
107. Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 2005;65:879-904.
108. Boyd M, Gustafson K, McMahon J, Discovery of cyanovirin-N, a novel HIV-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997;41:1521-30.
109. Bewley C, Otero-Quintero S. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. J Am Chem Soc 2001;123:3892-902.
110. Witvrouw M, Fikkert V, Hantson A, et al. Resistance of HIV-1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol 2005;79:7777-84.
111. Vermeire K, Zhang Y, Princen K, et al. CADA inhibits HIV and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002;302:342-53.
112. Vermeire K, Schols D. Specific CD4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003;74:667-75.
113. Bell T, Anugu S, Bailey P, et al. Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues. J Med Chem 2006;49:1291-312.
114. Moore J, Doms R. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003;100:10598-602.
115. Heveker N. Chemokine receptors as anti-retroviral targets. Curr Drug Targets 2001;2:21-39.
116. Ryser H, Fluckiger R. Progress in targeting HIV-1 entry. Drug Discov Today 2005;10:1085-94.
117. Zou Y, Kottmann A, Kuroda M, Taniuchi I, Littman D. Function of the chemokine receptor CXCR4 in hematopoiesis and in cerebellar development. Nature 1998;393:595-9
118. Ma Q, Jones D, Borghesani P, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998;95:9448-53.
119. Liu R, Paxton W, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77
120. Bleul C, Farzan M, Choe H, et al. The lymphocyte chemo-attractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-33.
121. Heveker N, Montes M, Germeroth L, et al. Dissociation of the signaling and antiviral properties of SDF-1-derived small peptides. Curr Biol 1998;8:369-76.
122. Zhou N, Luo Z, Luo J, et al. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J Biol Chem 2002;277:17476-85.
123. Dettin M, Pasquato A, Scarinci C, Zanchetta M, De Rossi A, Di Bello C. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1. J Med Chem 2004;47:3058-64.
124. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran C. HAART: current state of the art, new agents and their pharmacologic interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-43.
125. Borkow G, Lapidot A. Multi-targeting the entrance door to block HIV-1. Curr Drug Targets Infect Disord 2005;5:3-15.
126. Nakashima H, Masuda M, Murakami T, et al. Anti-HIV activity of a novel synthetic peptide, T22 ([Tyr-5, 12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother 1992;36:1249-55.
127. Tamamura H, Murakami T, Masuda M, et al. Structure-activity relationships of an anti-HIV peptide, T22. Biochem Biophys Res Commun 1994;205:1729-35.
128. Xu Y, Tamamura H, Arakaki R, et al. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. AIDS Res Hum Retroviruses 1999;20;15:419-27.
129. Arakaki R, Tamamura H, Premanathan M, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999;73:1719-23.
130. Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998;253:877-82.
131. Tamamura H, Hiramatsu K, Mizumoto M, et al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org Biomol Chem 2003;1:3663-9.
132. O'Brien W, Sumner-Smith M, Mao S, Sadeghi S, Zhao J, Chen I. Anti-HIV-1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol 1996;70:2825-31.
133. Doranz B, Filion L, Diaz-Mitoma F, et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses 2001;17:475-86.
134. Zhou N, Fang J, Acheampong E, Mukhtar M, Pomerantz R. Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a coreceptor by HIV-1. Virology 2003;312:196-203.
135. Zhou N, Zhang X, Fan X, et al. The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essential for its receptor function and coreceptor activity. Virology 2003;317:84-94.
136. Fenard D, Lambeau G, Valentin E, Lefebvre J, Lazdunski M, Doglio A. Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. J Clin Invest 1999;104:611-8.
137. Fenard D, Lambeau G, Maurin T, Lefebvre J, Doglio A. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol Pharmacol 2001;60:341-7.
138. Hamy F, Felder E, Heizmann G, et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997;94:3548-53.
139. Daelemans D, Schols D, Witvrouw M, et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of HIV replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 2000;57:116-24.
140. Schols D, Este J, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-56.
141. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol 2000;57:833-9.
142. Este J. HIV resistance to entry inhibitors. AIDS Rev 2001;3:121-32.
143. Hendrix C, Flexner C, MacFarland R, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44:1667-73.
144. Hendrix C, Collier A, Lederman M, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-62.
145. Hatse S, Princen K, De Clercq E, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol 2005;70:752-61.
146. Seibert C, Sakmar T. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr Pharm Des 2004;10:2041-62.
147. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003;100:4185-90.
148. Moore J, Stevenson M. New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000;1:40-9.
149. Mills S, DeMartino J. Chemokine receptor-directed agents as novel anti-HIV-1 therapies. Curr Top Med Chem 2004;4:1017-33.
150. Margolis L, Glushakova S, Grivel J, Murphy P. Blockade of CC chemokine receptor 5 (CCR5)-tropic HIV-1 replication in human lymphoid tissue by CC chemokines. J Clin Invest 1998;101: 1876-80.
151. Ylisastigui L, Vizzavona J, Drakopoulou E, et al. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages. AIDS 1998;12:977-84.
152. Pierson T, Doms R, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004;14:255-70.
153. Simmons G, Clapham P, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-9.
154. Mosier D, Picchio G, Gulizia R, et al. Highly potent RANTES analogs either prevent CCR5-using HIV-1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999;73:3544-50.
155. Proudfoot A, Power C, Hoogewerf A, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-603.
156. Torre V, Marozsan A, Albright J, et al. Variable sensitivity of CCR5-tropic HIV-1 isolates to inhibition by RANTES analogs. J Virol 2000;74:4868-76.
157. Oppermann M, Mack M, Proudfoot A, Olbrich H. Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J Biol Chem 1999;274:8875-85.
158. Polo S, Nardese V, De Santis C, et al. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur J Immunol 2000; 30:3190-8.
159. Hartley O, Dorgham K, Perez-Bercoff D, et al. HIV-1 entry inhibitors selected on living cells from a library of phage chemokines. J Virol 2003;77:6637-44.
160. Lederman M, Veazey R, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306:485-7.
161. Mack M, Pfirstinger J, Haas J, et al. Preferential targeting of CD4-CCR5 complexes with bifunctional inhibitors: a novel approach to block HIV-1 infection. J Immunol 2005;175:7586-93.
162. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-703.
163. Dragic T, Trkola A, Thompson D, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-44.
164. Takashima K, Miyake H, Kanzaki N, et al. Highly potent inhibition of HIV-1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother 2005;49:3474-82.
165. Baba M, Takashima K, Miyake H, et al. TAK-652 inhibits CCR5-mediated HIV-1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 2005;49:4584-91.
166. Tremblay C, Giguel F, Guan Y, Chou T, Takashima K, Hirsch M. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-HIV interactions with other antiretrovirals in vitro. Antimicrob Agents Chemother 2005;49:3483-5.
167. Nishikawa M, Takashima K, Nishi T, et al. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob Agents Chemother 2005;49:4708-15.
168. Tagat J, McCombie S, Steensma R, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. Bioorg Med Chem Lett 2001;11:2143-6.
169. Palani A, Shapiro S, Clader J, et al. Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1′-[(2,4-dimethyl-3- pyridinyl) carbonyl]-4′-methyl-1,4′- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J Med Chem 2001;44:3339-42.
170. Strizki J, Xu S, Wagner N, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-23.
171. Este J. Virus entry as a target for anti-HIV intervention. Curr Med Chem 2003;10:1617-32.
172. Strizki J, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against HIV-1. Antimicrob Agents Chemother 2005;49:4911-9.
173. Trkola A, Kuhmann S, Strizki J, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
174. Marozsan A, Kuhmann S, Morgan T, et al. Generation and properties of a HIV-1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005;338:182-99.
175. Wood A, Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem 2005;43:239-71.
176. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-HIV type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32.
177. Fatkenheuer G, Pozniak A, Johnson M, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2.
178. Maeda K, Yoshimura K, Shibayama S, et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001;276:35194-200
179. Maeda K, Nakata H, Koh Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 HIV-1 in vitro. J Virol 2004;78:8654-62.
180. Trkola A, Ketas T, Nagashima K, et al. Potent, broad-spectrum inhibition of HIV-1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001;75:579-88.
181. Clanton D, Buckheit R Jr., Terpening S, et al. Novel sulfonated and
182. Howard O, Oppenheim J, Hollingshead M, et al. Inhibition of in vitro and in vivo HIV replication by a distamycin analog that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. J Med Chem 1998;41:2184-93.
183. Howard O, Korte T, Tarasova N, et al. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukoc Biol 1998;64:6-13.
184. Veazey R, Klasse P, Ketas T, et al. Use of a small molecule CCR5 inhibitor in macaques to treat SIV infection or prevent simian-HIV infection. J Exp Med 2003;198:1551-62.
185. Wolinsky S, Veazey R, Kunstman K, et al. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 2004;328:19-29.
186. Chan D, Fass D, Berger J, Kim P. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73.
187. Root M, Kay M, Kim P. Protein design of an HIV-1 entry inhibitor. Science 2001;291:884-8
188. Wild C, Shugars D, Greenwell T, McDanal C, Matthews T. Peptides corresponding to a predictive alpha-helical domain of HIV-1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91:9770-4.
189. Kilby J, Hopkins S, Venetta T, DiMassimo B, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-7.
190. Lalezari J, DeJesus E, Northfelt D, et al. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003;8:279-87.
191. Lalezari J, Eron J, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17:691-8.
192. Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
193. Eckert D, Malashkevich V, Hong L, Carr P, Kim P. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999;99:103-15.
194. Greenberg M, McDanal C, Stanfield-Oakley S, et al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. 8th CROI 2001.
195. Lalezari J, Bellos N, Sathasivam K, et al. T-1249 retains potent antiretroviral activity in patients who had experienced virologic failure while on an enfuvirtide-containing treatment regimen. J Infect Dis 2005;191:1155-63.
196. Markovic I, Clouse K. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2004;2:223-34.
197. Martin-Carbonero L. Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Rev 2004;6:61.
198. Delmedico M, Bray B, Cammack N. Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. 13th CROI Denver. 2006 [abstract].
199. Green D, Tidor B. Design of improved protein inhibitors of HIV-1 cell entry: Optimization of electrostatic interactions at the binding interface. Proteins 2005;60:644-57.
200. Markovic I, Stantchev T, Fields K, et al. Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood 2004;103:1586-94.
201. Mayaux J, Bousseau A, Pauwels R, et al. Triterpene derivatives that block entry of HIV-1 into cells. Proc Natl Acad Sci USA 1994;91:3564-8.
202. Soler F, Poujade C, Evers M, et al. Betulinic acid derivatives: a new class of specific inhibitors of HIV-1 entry. J Med Chem 1996;39:1069-83.
203. Sun I, Chen C, Kashiwada Y, Wu J, Wang H, Lee K. Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid. J Med Chem 2002;45:4271-5.
204. Lu L, Liu S, Jiang S, Wu S. Tannin inhibits HIV-1 entry by targeting gp41. Acta Pharmacol Sin 2004;25:213-8.
205. Dai S, Dou G, Qiang X, et al. Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 2005;26:1274-80.
206. Debnath A, Radigan L, Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the HIV-1. J Med Chem 1999;42:3203-9.
207. Naicker K, Jiang S, Lu H, et al. Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methyl- phenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives. Bioorg Med Chem 2004;12:1215-20.
208. Armand-Ugon M, Clotet-Codina I, Tintori C, et al. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology 2005;343:141-9.
209. Harrison P, Rosenberg Z, Bowcut J. Topical microbicides for disease prevention: status and challenges. Clin Infect Dis 2003;36:1290-4.
210. D'Cruz O, Uckun F. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004;10:315-36.
211. Howett M, Kuhl J. Microbicides for prevention of transmission of sexually transmitted diseases. Curr Pharm Des 2005;11:3731-46.
212. Dhawan D, Mayer K. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J Infect Dis 2006;193:36-44.
213. Colleluori D, Tien D, Kang F, et al. Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif 2005;39:229-36.
214. Tsai C, Emau P, Jiang Y, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004;20:11-8.
215. Jiang Y, Emau P, Cairns J, et al. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2005;21:207-13.
216. Scordi-Bello I, Mosoian A, He C, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-HIV activities and mechanisms of action. Antimicrob Agents Chemother 2005;49:3607-15.
217. Keller M, Zerhouni-Layachi B, Cheshenko N, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006;193:27-35.
218. Hartmann S, Wigdahl B, Neely E, et al. Biochemical analysis of human milk treated with sodium dodecyl sulfate, an alkyl sulfate microbicide that inactivates HIV-1. J Hum Lact 2005;22:61-74.
219. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 2002;360:971-7.
220. Catalone B, Kish-Catalone T, Neely E, et al. Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agents Chemother 2005;49:1509-20.
221. Freed E, Myers D, Risser R. Identification of the principal neutralizing determinant of HIV-1 as a fusion domain. J Virol 1991; 65:190-4.
222. Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic HIV isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-54.
223. De Jong J, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the HIV-1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992;66:6777-80.
224. Shioda T, Levy J, Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of HIV-1. Proc Natl Acad Sci USA 1992;89:9434-8.
225. Carrillo A, Trowbridge D, Westervelt P, Ratner L. Identification of HIV1 determinants for T lymphoid cell line infection. Virology 1993;197:817-24.
226. De Wolf F, Hogervorst E, Goudsmit J, et al. and WHO Network for HIV Isolation and Characterization. Syncytium-inducing and non-syncytium-inducing capacity of HIV-1 subtypes other than B: phenotypic and genotypic characteristics. AIDS Res Hum Retroviruses 1994;10:1387-400.
227. Abebe A, Demissie D, Goudsmit J, et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999; 13:1305-11.
228. Todd B, Kedar P, Pope J. Syncytium induction in primary CD4+ T-cell lines from normal donors by HIV-1 isolates with non-syncytium-inducing genotype and phenotype in MT-2 cells. J Virol 1995;69:7099-105.
229. Moyle G, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72.
230. Korber B, MacInnes K, Smith R, Myers G. Mutational trends in V3 loop protein sequences observed in different genetic lineages of HIV-1. J Virol 1994;68:6730-44.
231. Yamaguchi Y, Gojobori T. Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts. Proc Natl Acad Sci USA 1997;94:1264-9.
232. Seillier-Moiseiwitsch F, Margolin, B, Swanstrom R. Genetic variability of HIV: statistical and biological issues. Ann Rev Genet 1994;28:559-96.
233. Briggs D, Tuttle D, Sleasman J, Goodenow M. Envelope V3 amino acid sequence predicts HIV-1 phenotype (coreceptor usage and tropism for macrophages). AIDS 2000;14:2937-9.
234. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of HIV-1 from envelope variable loop 3 sequence using neural networks. Virology 2001;288:51-62.
235. Yamaguchi-Kabata Y, Gojobori T. Reevaluation of amino acid variability of HIV-1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes. J Virol 2000;74:4335-50.
236. Shannon C. A mathematical theory of communication. Bell Syst Technol J 1948;27:379-423.
237. Nagashima K, Thompson D, Rosenfield S, Maddon P, Dragic T, Olson W. HIV-1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001;183:1121-5.
238. Jacobson J, Israel R, Lowy I, et al. Treatment of advanced HIV-1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004;48:423-9.
239. Hanna,G, Lalezari J, Hellinger J. Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. 11th CROI San Francisco. 2004 [abstract].
240. Low-Beer N, Gabe R, McCormack S, Kitchen V, Lacey C, Nunn A. Dextrin sulfate as a vaginal microbicide: randomized, double-blind, placebo-controlled trial including healthy female volunteers and their male partners. J Acquir Immune Defic Syndr 2002;31:391-8.
241. McCormack S, Jespers V, Low-Beer N, et al. A dose-ranging phase I study of dextrin sulphate, a vaginal microbicide, in HIV-negative and HIV-positive female volunteers. Sex Transm Dis 2005;32:765-70.
242. Wallace T, Gamba-Vitalo C, Loveday K, Cossum P. Acute, multiple-dose, and genetic toxicology of AR177, an anti-HIV oligonucleotide. Toxicol Sci 2000;53:63-70.
243. Murakami T, Yoshida A, Tanaka R. KRH-2731: An orally bioavailable CXCR4 antagonist is a potent inhibitor of HIV-1 infection. 11th CROI, San Francisco, 2004 [abstract].
244. Tanaka Y, Yokuma K, Tanaka R. Development of novel orally bioavailable CXCR4 antagonists, KRH-3955 and KRH-3140: binding specificity, pharmacokinetics and anti-HIV-1 activity in vivo and in vitro. 13th CROI, Denver, 2006 [abstract].
245. Simmons G, Clapham P, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-9.
246. Veazey R, Springer M, Marx P, Dufour J, Klasse P, Moore J. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005;11:1293-4.
247. Lalezari J, DeJesus E, Northfelt D, et al. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003;8:279-87.
248. Sista P, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004:18:1787-94.